Phase II Trial of Sorafenib in Combination With Capecitabine for the Treatment of Patients With Measurable Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Sorafenib (Primary) ; Capecitabine
- Indications Liver cancer
- Focus Adverse reactions
- 04 Jun 2013 Planned end date changed from 1 Sep 2016 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 04 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Nov 2012 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.